Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Darling

Showing results (231-240 of 233) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 233 results.
The Journal of Extra-Corporeal Technology|July 17, 2020
Development of the Adult ECMO Specialist Certification ExaminationJeffrey B Riley, Mark T Lucas, Keith A Samolyk, et al.
Hepatology (Baltimore, Md.)|July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyMark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Pageof 24

Showing results (231-240 of 233) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 233 results.
The Journal of Extra-Corporeal Technology|July 17, 2020
Development of the Adult ECMO Specialist Certification ExaminationJeffrey B Riley, Mark T Lucas, Keith A Samolyk, et al.
Hepatology (Baltimore, Md.)|July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyMark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
Pageof 24